Ganesh Benzoplast Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
GANESHBE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 3.4 pts more than its Oil peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved Standalone and Consolidated Audited Financial Results for Q4 and FY ended March 31, 2025, along with an unmodified (clean) auditor's opinion from M/s Mittal & Associates. Consolidated PAT (without exceptional items) rose 18% YoY to Rs. 723 million from Rs. 614 million, driven by a strong 243% jump in the Chemical division's pre-tax profit to Rs. 206 million. However, total consolidated revenue declined about 22% to Rs. 3,743 million from Rs. 4,770 million, mainly due to a planned drop in low-margin EPC business in the LST division. The company booked Rs. 447.31 million as exceptional items, including a one-time Rs. 438.63 million settlement with Morgan Securities and an Rs. 8.68 million GST liability, reducing reported PAT to Rs. 380.86 million (down ~38%). The Board also appointed Cost, Internal, and Secretarial Auditors for FY26.
Underlying profitability is healthy with 18% growth in core PAT, but reported earnings are dragged by a large one-time legal settlement. Shareholders should view the headline PAT decline as non-recurring, while the revenue contraction in LST appears strategic. Overall a neutral-to-mildly positive signal for long-term investors given clean audit and strong chemical business momentum.